- Home
- SDHC vs HUMA Comparison
SDHC vs HUMA Comparison
Compare SDHC & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDHC | HUMA |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.0M | 182.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SDHC | HUMA |
|---|---|---|
| Price | $15.83 | $1.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $16.70 | $10.00 |
| AVG Volume (30 Days) | 54.3K | ★ 5.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $975,463,000.00 | N/A |
| Revenue This Year | $0.58 | N/A |
| Revenue Next Year | $6.61 | $731.05 |
| P/E Ratio | $20.32 | ★ N/A |
| Revenue Growth | ★ 27.57 | N/A |
| 52 Week Low | $15.00 | $0.88 |
| 52 Week High | $23.50 | $3.49 |
Technical Indicators
Market Signals| Indicator | SDHC | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 52.05 |
| Support Level | N/A | $0.92 |
| Resistance Level | $21.44 | $1.25 |
| Average True Range (ATR) | 0.92 | 0.11 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 4.96 | 49.53 |
Price Performance
Historical ComparisonAbout SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.